









市場
/
株式
/
nasdaq-pcvx
/

Vaxcyte Inc

PCVX

47.650USD

-0.160-0.33%

終値 12/24, 16:00（ET）15分遅れの株価

6.20B時価総額

損失額直近12ヶ月PER



Vaxcyte Inc

47.650

-0.160-0.33%

概要企業名金融分析

概要

企業名

金融

分析

詳細情報 Vaxcyte Inc 企業名

Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.

Vaxcyte Incの企業情報



企業コードPCVX

会社名Vaxcyte Inc

上場日Jun 12, 2020

最高経営責任者「CEO」Pickering (Grant E)

従業員数414

証券種類Ordinary Share

決算期末Jun 12

本社所在地825 Industrial Road, Ste. 300

都市SAN CARLOS

証券取引所NASDAQ OMX - NASDAQ BASIC

国United States of America

郵便番号94070

電話番号16508370111

ウェブサイトhttps://vaxcyte.com/

企業コードPCVX

上場日Jun 12, 2020

最高経営責任者「CEO」Pickering (Grant E)

Vaxcyte Incの経営陣



会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Grant E. Pickering

Chief Executive Officer, Co-Founder, Director

658.46K

-2.69%

Mr. Andrew L. Guggenhime

President, Chief Financial Officer

75.59K

-9.54%

Mr. James (Jim) Wassil

Executive Vice President, Chief Operating Officer

27.26K

-20.53%

Mr. Mikhail Eydelman, J.D.

Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary

12.60K

-28.82%

Dr. Carlos V. Paya, M.D., Ph.D.

Independent Chairman of the Board

8.67K

+54.06%

Ms. Teri Loxam

Independent Director

8.67K

+54.06%

Mr. Jacks Lee

Independent Director

3.04K

Mr. John P. Furey

Independent Director

3.04K

Dr. Olivier Brandicourt

Independent Director

1.15K

Dr. Heath Lukatch, Ph.D.

Independent Director

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Grant E. Pickering

Chief Executive Officer, Co-Founder, Director

658.46K

-2.69%

Mr. Andrew L. Guggenhime

President, Chief Financial Officer

75.59K

-9.54%

Mr. James (Jim) Wassil

Executive Vice President, Chief Operating Officer

27.26K

-20.53%

Mr. Mikhail Eydelman, J.D.

Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary

12.60K

-28.82%

Dr. Carlos V. Paya, M.D., Ph.D.

Independent Chairman of the Board

8.67K

+54.06%

Ms. Teri Loxam

Independent Director

8.67K

+54.06%

収益内訳

会社から関連データがまだ開示されていません。

会社から関連データがまだ開示されていません。

事業別

地域別

会社から関連データがまだ開示されていません。

株主

更新時刻: Sat, Nov 15

株主統計

種類

株主統計

比率

Janus Henderson Investors

10.01%

The Vanguard Group, Inc.

9.39%

RA Capital Management, LP

9.14%

Fidelity Management & Research Company LLC

7.90%

BlackRock Institutional Trust Company, N.A.

6.41%

他の

57.15%

株主統計

比率

Janus Henderson Investors

10.01%

The Vanguard Group, Inc.

9.39%

RA Capital Management, LP

9.14%

Fidelity Management & Research Company LLC

7.90%

BlackRock Institutional Trust Company, N.A.

6.41%

他の

57.15%

種類

株主統計

比率

Investment Advisor

43.44%

Investment Advisor/Hedge Fund

31.40%

Hedge Fund

19.35%

Venture Capital

11.37%

Research Firm

2.23%

Bank and Trust

0.97%

Sovereign Wealth Fund

0.75%

Individual Investor

0.68%

Pension Fund

0.61%

機関投資家保有株



更新時刻: Wed, Oct 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q3

668

148.53M

114.41%

-14.14M

2025Q2

654

150.97M

116.29%

-1.23M

2025Q1

669

149.26M

115.73%

-5.52M

2024Q4

629

143.44M

111.44%

-3.61M

2024Q3

579

138.80M

114.99%

+5.28M

2024Q2

508

125.57M

113.86%

-5.08M

2024Q1

487

122.06M

113.01%

+8.05M

2023Q4

444

106.09M

111.72%

-6.02M

2023Q3

417

110.70M

121.97%

-7.51M

2023Q2

397

109.13M

122.07%

+11.09M

詳細を見る

株主動向



会社名

保有株式数

比率

変動額

変動率

日付

Janus Henderson Investors

14.69M

11.32%

+151.06K

+1.04%

Jun 30, 2025

The Vanguard Group, Inc.

11.97M

9.22%

-48.12K

-0.40%

Jun 30, 2025

RA Capital Management, LP

11.97M

9.22%

-223.16K

-1.83%

Jun 30, 2025

Fidelity Management & Research Company LLC

10.05M

7.74%

-677.06K

-6.31%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

9.05M

6.97%

-85.53K

-0.94%

Jun 30, 2025

T. Rowe Price Investment Management, Inc.

6.00M

4.62%

+3.30M

+122.04%

Jun 30, 2025

Wellington Management Company, LLP

4.95M

3.82%

-1.46M

-22.79%

Jun 30, 2025

State Street Investment Management (US)

4.94M

3.81%

+534.55K

+12.13%

Jun 30, 2025

D. E. Shaw & Co., L.P.

3.09M

2.38%

+2.22M

+255.86%

Jun 30, 2025

Paradigm BioCapital Advisors LP

3.37M

2.6%

+1.68M

+98.81%

Jun 30, 2025

詳細を見る

配当金



過去5年間の配当金総支払額は 0.00 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

データなし

株式分割



日付

種類

比率

データなし

日付

種類

比率

データなし

よくある質問

Vaxcyte Incの上位5名の株主は誰ですか？



Vaxcyte Incの上位5名の株主は以下のとおりです。
Janus Henderson Investorsは14.69M株を保有しており、これは全体の11.32%に相当します。
The Vanguard Group, Inc.は11.97M株を保有しており、これは全体の9.22%に相当します。
RA Capital Management, LPは11.97M株を保有しており、これは全体の9.22%に相当します。
Fidelity Management & Research Company LLCは10.05M株を保有しており、これは全体の7.74%に相当します。
BlackRock Institutional Trust Company, N.A.は9.05M株を保有しており、これは全体の6.97%に相当します。